Home » Mónica Martín de Bustamante

Mónica Martín de Bustamante

CEO & Managing Director

Ms. Martin de Bustamante’s career has focused on pharmaceutical global pricing and market access issues for biopharmaceutical and pharmaceutical products. Her time has been apportioned between the mature and emerging markets, with deep expertise in the USA, EU5, CAN, and JPN. Ms. Martin de Bustamante has worked across the major therapeutic areas (oncology, cardiovascular, neurology, metabolic, autoimmune, gastrointestinal, respiratory, etc.) collaborating on products from their early development, through launch, and following through their lifecycle.

Much of Ms. Martin de Bustamante’s work to date has centered around understanding the barriers to access and reimbursement challenges posed by evolving healthcare systems and evidence requirements. She has extensive global experience in early and late-stage pricing, market access strategies, value proposition development, lifecycle management, generic or biosimilar erosion counterstrategies, and patient support programs.

Ms. Martin de Bustamante has worked within the life sciences consulting industry for over 10 years. She holds a Bachelor’s in Biomedical Engineering and a Bachelors in Romance Languages & Engineering Sciences from Dartmouth College and speaks both Spanish and English at native level fluency.

Connect with Mónica Martín de Bustamante


+1 650 823 9568


Published Articles

ISPOR Annual 2020: Re-Submissions with RWE: Can They Help Change Your Benefit Rating?

A research poster that aims to understand the role of RWE in re-submissions and determine if this type of evidence can help to improve HTA outcomes when products are re-assessed by the Haute Autorité de Santé (HAS) in France and Gemeinsamer Bundesausschuss (G-BA) in Germany.

ISPOR Annual 2020: OCM to OCF: Implications for Total Cost of Care

A research poster that aims to map the limitations of the OCM to the proposed features of the 2021 OCF model in order to evaluate whether the OCF is more likely to successfully reduce total cost of care.

ISPOR Annual 2020: Evaluating the HTA Impact of Real-World Evidence from Formal Orphan Drug Registries

This research poster aims to perform a comparative assessment of the formal registry requirements in Germany and Brazil for orphan therapies with limited clinical evidence in order to pinpoint the future role of real-world evidence (RWE) in health technology assessments (HTAs).

Developing an Early Stage Biopharmaceutical Asset in Europe: Navigating Treacherous Waters

When biopharmaceutical products launch in the European Union, even experienced manufacturers can struggle to overcome the demanding standards of European payers. The complex market authorisation requirements and subsequent access decisions across 28 countries can lead to challenging timelines and confusing rollouts. Unfortunately for manufacturers, the future of European commercial planning is likely to become more challenging, as nations look to raise evidence standards and increase the scrutiny of pricing. Looking ahead over the next ten years, CBPartners is tracking many policy and payer trends which will affect the playing field for future launches. Examining these key trends in detail can provide further understanding of how manufacturers can create an “Early Asset Success Plan” for new products.

PDx Drugs: Emerging Secrets to Success (and Failures)

As a class, manufacturers of PDxs (PD1s / PD-L1) are enjoying great success when it comes to marketing authorisation, with four of the five brands achieving multiple FDA and EMA approvals. CBPartners takes a closer look at the successes and failures in this highly competitive class of drugs.

Rome Wasn’t Built in a Day Either: Greece is Back Again with New Pricing and Reimbursement Policy Reforms

CBPartners explores the new pricing and reimbursement policy reforms in Greece.